-
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
Tuesday, June 1, 2021 - 8:58am | 186Read More...Akebia Therapeutics Inc (NASDAQ: AKBA) and its collaborator Otsuka Holdings (OTC: OTSKY) have announced that the FDA has accepted to review vadadustat's marketing application for anemia due to chronic kidney disease. The application covers both adult patients, on...
-
Ardelyx Stock Plummets As Review Period For Tenapanor US Application Pushed By 3 Months
Friday, April 30, 2021 - 6:34am | 171Read More...The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for Ardelyx Inc's (NASDAQ: ARDX) tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. The agency asked the company to submit additional...
-
FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat
Wednesday, April 7, 2021 - 5:54am | 380Read More...FibroGen Inc (NASDAQ: FGEN) stock plummeted after hours on Tuesday after a murky disclosure for roxadustat, the company’s anemia treatment in chronic kidney disease patients. While preparing for an advisory committee meeting ahead of potential approval of roxadustat, FibroGen...
-
Reata Pharma Shares Are Trading Higher After Filing US Application In Alport Syndrome-Related Kidney Disease
Monday, March 1, 2021 - 1:54pm | 243Read More...Reata Pharmaceuticals Inc (NASDAQ: RETA) has submitted a marketing application to the FDA for bardoxolone methyl (bardoxolone) to treat chronic kidney disease caused by Alport syndrome. Alport syndrome is a rare, genetic form of kidney disease caused by mutations in the genes...
-
Evotec, Chinook Therapeutics Ink Development Pact For Chronic Kidney Diseases Therapies
Monday, March 1, 2021 - 6:22am | 240Read More...Chinook Therapeutics Inc (NASDAQ: KDNY) and Evotec SE (OTCMKTS: EVTCY) have collaborated for the discovery and development of precision medicine therapies for patients with chronic kidney diseases (CKD). Based on Evotec's proprietary comprehensive molecular datasets,...
-
Keryx Biopharmaceuticals Surges 20% Following Positive Kidney Disease Drug Data
Tuesday, March 29, 2016 - 8:54am | 241Read More...Shares of Keryx Biopharmaceuticals (NASDAQ: KERX), a biopharmaceutical company that focuses on the treatment of renal diseases, gained more than 20 percent early Tuesday morning. Keryx Biopharmaceuticals announced positive top-line results from its pivotal Phase 3 study of ferric citrate for the...
-
Why Shares Of Rockwell Medical Are Up Huge
Monday, January 26, 2015 - 11:01am | 257Read More...Shares of Rockwell Medical Inc (NASDAQ: RMTI) were trading higher by more than percent after the company announced the FDA has approved its Triferic (ferric pyrophosphate solution) intended for the maintenance of hemoglobin in adult patients with hemodialysis dependent chronic kidney disease....
